Factors for severe outcomes following SARS-CoV-2 infection in people with cystic fibrosis in Europe

Andreas Jung 1,50, Annalisa Orenti 2,50, Fiona Dunlevy 3,50, Elina Aleksejeva 4, Egil Bakkeheim 5, Vladimir Bobrovichny 6, Siobhán B. Carr 7,8, Carla Colombo 9, Harriet Corvol 10,11, Rebecca Cosgriff 11, Géraldine Danau 12, Deniz Dogru 13, Pavel Drevinek 14, Andrea Dugac Vukic 15, Isabelle Fajac 16,17, Alice Fox 18, Stojka Fustik 18, Vincent Gulmans 19, Satenik Harutyunyan 20, Elpis Hatzigiorou 21, Irena Kasmí 22, Hana Kayserová 23, Elena Kondratyeva 24, Uroš Krivec 25, Halyna Makukh 26, Kestutis Malakauskas 27, Edward F. McKone 28, Meir Mei-Zahav 29,30, Isabelle de Monestrol 31, Hanne Vebert Olesen 32, Rita Padoan 33,34, Tsitsino Parulava 35, Maria Dolores Pastor-Vivero 36, Luísa Pereira 37, Guergana Petrova 38, Andreas Pfleger 39, Liviu Pop 40, Jacqui G. van Rens 3, Milan Rodic 41, Marc Schlesser 42, Valérie Storms 43, Oxana Turcu 44, Lukasz Woźniacki 45, Panayiotis Yiallouros 46, Anna Zolin 2, Damian G. Downey 47,48,51 and Lutz Naehrlíč 2,49,51

1Paediatric Pulmonology, University Children’s Hospital Zurich, Zurich, Switzerland. 2Dept of Clinical Sciences and Community Health, Laboratory of Medical Statistics, Epidemiology and Biometry G.A. Maccacaro, University of Milan, Milan, Italy. 3European Cystic Fibrosis Society, Karup, Denmark. 4Dept of Pneumology, Children’s Clinical University Hospital, Riga Stradiņš University, Riga, Latvia. 5Dept of Paediatrics, Norwegian Cystic Fibrosis Registry, Oslo University Hospital, Oslo, Norway. 6Belarusian Republic Children’s Center of Pulmonology and Cystic Fibrosis, Pulmonary Department, 3rd City Children’s Clinical Hospital, Minsk, Belarus. 7Dept of Respiratory Paediatrics, Royal Brompton Hospital, London, UK. 8NHLI, Imperial College, London, UK. 9Dept of Pathophysiology and Transplantation, Cystic Fibrosis Reference Center of Lombardia Region, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy. 10Pediatric Pulmonology Dept and Cystic Fibrosis Center, Sorbonne Université, Centre de Recherche Saint-Antoine, Inserm UMR_S938, Assistance Publique-Hôpitaux de Paris, Hôpital Trousseau, Paris, France. 11Cystic Fibrosis Trust, London, UK. 12Sciensano, Epidemiology and Public Health, Health Services Research, Brussels, Belgium. 13Cystic Fibrosis Registry of Turkey, Ankara, Turkey. 14Dept of Medical Microbiology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic. 15University Hospital Centre Zagreb, Cystic Fibrosis Centre – Paediatrics and Adults, Zagreb, Croatia. 16Université Paris Descartes, Sorbonne Paris Cité, Paris, France. 17AP-HP, Hôpital Cochin, Service de Physiologie et Explorations Fonctionnelles, Paris, France. 18Centre for Cystic Fibrosis, University Children’s Hospital, Skopje, North Macedonia. 19Dutch Cystic Fibrosis Foundation (NCF), Baarn, The Netherlands. 20Yerevan University CF Centre, Muratsan Hospital, Yerevan, Armenia. 21Cystic Fibrosis Unit, Hippokration General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece. 22Dept of Paediatrics, “Mother Thereza” Hospital Center, Tirana, Albania. 23Cystic Fibrosis Centre, University Hospital of Bratislava, Bratislava, Slovakia. 24Clinical Research Dept of Cystic Fibrosis “Research Centre for Medical Genetics”, Moscow, Russian Federation. 25Dept of Paediatric Pulmonology, University Children’s Hospital Ljubljana, University Medical Centre Ljubljana, Slovenia. 26Institute of Hereditary Pathology, Ukrainian National Academy of Medical Sciences, Lviv, Ukraine. 27Adult Cystic Fibrosis Center, Dept of Pulmonology, Lithuanian University of Health Sciences, Kaunas, Lithuania. 28Dept of Pulmonology of Vincent’s University Hospital & University College Dublin School of Medicine, Dublin, Ireland. 29Pulmonary Institute, Schneider Children’s Medical Center of Israel, Petah Tikva, Israel. 30Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 31Stockholm CF Centre, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden. 32Dept of Pediatrics and Adolescent Medicine, Cystic Fibrosis Center, Aarhus University Hospital, Aarhus, Denmark. 33Dept of Paediatrics, Cystic Fibrosis Regional Support Centre, University of Brescia, Brescia. 34Scientific Board of Italian CF Registry, Rome, Italy. 351, Tsitsishvili Children’s Clinic, CF Centre, Tbilisi, Georgia. 36Pediatric Pneumology and Cystic Fibrosis Unit, Osakidetza, Hospital Universitario Cruces, Bizkaia, Spain. 37Centre for Cystic Fibrosis, Hospital de Santa Maria, Lisbon, Portugal. 38Pediatric Clinic, Alexandrovsk University Hospital and Allergyology, Medical University of Graz, Graz, Austria. 39Dept of Pediatrics and Adolescent Medicine, Division of Pediatric Pulmonology and Allergyology, Medical University of Cyprus, Nicosia, Cyprus. 40Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University Belfast, Belfast, UK. 41Regional Respiratory Centre, Belfast City Hospital, Belfast, UK. 42Universities of Giessen and Marburg Lung Center, German Center of Lung Research, Justus-Liebig-University Giessen, Giessen, Germany. 50Co-first authors. 51Co-senior authors.

Corresponding author: Andreas Jung (Andreas.Jung@kispi.uzh.ch)
In a European study of #SARSCoV2 infection in 828 people with #cysticfibrosis, those with moderate–severe lung disease, CF-related diabetes and lung transplant had poorer outcomes. People with CF, especially these groups, should shield in priority. https://bit.ly/3vPjD2f

Cite this article as: Jung A, Orenti A, Dunlevy F, et al. Factors for severe outcomes following SARS-CoV-2 infection in people with cystic fibrosis in Europe. ERJ Open Res 2021; 7: 00411-2021 [DOI: 10.1183/23120541.00411-2021]

Abstract

**Background** Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in people with cystic fibrosis (pwCF) can lead to severe outcomes.

**Methods** In this observational study, the European Cystic Fibrosis Society Patient Registry collected data on pwCF and SARS-CoV-2 infection to estimate incidence, describe clinical presentation and investigate factors associated with severe outcomes using multivariable analysis.

**Results** Up to December 31, 2020, 26 countries reported information on 828 pwCF and SARS-CoV-2 infection. Incidence was 17.2 per 1000 pwCF (95% CI: 16.0–18.4). Median age was 24 years, 48.4% were male and 9.4% had lung transplants. SARS-CoV-2 incidence was higher in lung-transplanted (28.6; 95% CI: 22.7–35.5) versus non-lung-transplanted pwCF (16.6; 95% CI: 15.4–17.8) (p≤0.001). SARS-CoV-2 infection caused symptomatic illness in 75.7%. Factors associated with symptomatic SARS-CoV-2 infection were age >40 years, at least one F508del mutation and pancreatic insufficiency. Overall, 23.7% of pwCF were admitted to hospital, 2.5% of those to intensive care, and regretfully 11 (1.4%) died. Hospitalisation, oxygen therapy, intensive care, respiratory support and death were 2- to 6-fold more frequent in lung-transplanted versus non-lung-transplanted pwCF. Factors associated with hospitalisation and oxygen therapy were lung transplantation, cystic fibrosis-related diabetes (CFRD), moderate or severe lung disease and azithromycin use (often considered a surrogate marker for *Pseudomonas aeruginosa* infection and poorer lung function).

**Conclusion** SARS-CoV-2 infection yielded high morbidity and hospitalisation in pwCF. PwCF with forced expiratory volume in 1 s <70% predicted, CFRD and those with lung transplants are at particular risk of more severe outcomes.

Introduction

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected over 79 million people worldwide in 2020, causing 1.7 million deaths [1].

Given that viral infection can cause pulmonary exacerbations and hasten lung function decline [2–4], people with cystic fibrosis (CF) (pwCF) took early steps to protect themselves from infection by shielding [5, 6]. Nonetheless, adult and paediatric pwCF have been infected [7–9].

We recently assessed the incidence of SARS-CoV-2 infection in a cohort of 130 pwCF in Europe up to June 30, 2020 [7]. Other national and global studies have also assessed incidence and outcomes of SARS-CoV-2 infection in pwCF during the first wave of the pandemic [8, 10–12]. Lung-transplanted pwCF appear to have worse outcomes than those without lung transplant. However robust multivariable data are still lacking regarding risk factors, as well as up-to-date incidence estimates.

Here we expand our previously described cohort [7] to include European pwCF who were diagnosed with SARS-CoV-2 infection up to December 31, 2020. In this cohort of 828 pwCF, we update SARS-CoV-2 incidence, and provide the first large, detailed analysis of clinical presentation (including individual symptoms) and identification of risk factors associated with poorer outcomes.

Methods

**Study design**

The methodology of this prospective observational study has been previously described in a paper presenting data collected between February 1, 2020 and June 30, 2020 [7]. Briefly, data regarding pwCF with PCR-confirmed SARS-CoV-2 infection were collected from CF centres participating in the European Cystic Fibrosis Society Patient Registry (ECFSPR). Cases diagnosed by computed tomography scan, serology or antigen test without PCR confirmation were excluded. Data were reported directly to ECFSPR using a standardised case report form, except for Belgium, France, Germany and the UK who contributed data via their national registries. Two data sources were reported for Italy (national registry and the Italian CF society), with no double cases reported.
We collected data about demographics, pre-infection CF characteristics (latest data available, collected within 12 to 18 months before infection depending on the national data collection strategy) and information about SARS-CoV-2 infection regarding diagnosis, symptoms, complications, treatments and outcomes. Where appropriate, variables were defined according to ECFSPR standards (www.ecfs.eu/projects/ecfs-patient-registry/Variables-Definitions). Per cent predicted forced expiratory volume in 1 s (ppFEV1) is referred to as mild (>70), moderate (>40–70) or severe (≤40) lung disease [13].

Each participating centre or national registry has ethical approval and patients’ informed consent for data collection and ECFSPR participation, including consent that data may be used for future research.

Definitions of symptoms and outcomes

A pwCF was defined as symptomatic if they reported at least one symptom of SARS-CoV-2 infection. Symptoms were categorised as general, pulmonary, gastrointestinal or ear, nose and throat (ENT) and eye (see table 1). Outcomes were hospitalisation, intensive care, oxygen therapy, respiratory support and death (see table 1).

### TABLE 1 Symptoms and outcomes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in people with cystic fibrosis

| Subjects | Total | Non-lung transplant | Lung transplant |
|----------|-------|---------------------|-----------------|
| n (%)    | Missing | n (%) | Missing | n (%) | Missing |
| **Subjects n** | 828 | 750 | 78 |
| **Symptoms** | | | | |
| Presence of symptoms | 586 (75.7) | 54 | 528 (75.1) | 47 | 58 (81.7) | 7 |
| General symptoms | 467 (64.8) | 107 | 418 (64.2) | 99 | 49 (70.0) | 8 |
| Fever | 353 (43.9) | 23 | 311 (42.6) | 20 | 42 (56.0) | 3 |
| Fatigue | 228 (34.2) | 162 | 200 (33.3) | 150 | 28 (42.4) | 12 |
| Myalgia or arthralgia | 149 (22.4) | 163 | 128 (21.5) | 154 | 21 (30.4) | 9 |
| Headache | 114 (15.9) | 10 | 108 (16.4) | 10 | 6 (7.7) | 0 |
| Pulmonary symptoms | 405 (54.0) | 78 | 366 (53.9) | 71 | 39 (54.9) | 7 |
| Increased cough | 341 (43.2) | 39 | 311 (43.8) | 30 | 24 (36.9) | 13 |
| Increased dyspngea | 146 (18.6) | 43 | 122 (16.9) | 30 | 24 (36.9) | 13 |
| Chest tightness | 45 (5.5) | 8 | 42 (5.7) | 8 | 3 (3.8) | 0 |
| Wheezing | 14 (1.7) | 7 | 13 (1.7) | 7 | 1 (1.3) | 0 |
| Increased sputum | 96 (13.9) | 136 | 93 (15.0) | 131 | 3 (4.1) | 5 |
| Haemoptysis | 10 (1.2) | 4 | 10 (1.3) | 4 | 0 (0.0) | 0 |
| Pulmonary exacerbation | 124 (21.2) | 242 | 120 (22.2) | 210 | 4 (8.7) | 32 |
| Respiratory failure | 15 (2.7) | 271 | 11 (2.1) | 236 | 4 (9.3) | 35 |
| Gastrointestinal symptoms | 70 (8.5) | 7 | 63 (8.5) | 6 | 7 (9.1) | 1 |
| Diarrhoea | 37 (4.5) | 5 | 33 (4.4) | 4 | 4 (5.2) | 1 |
| Vomiting/nausea | 26 (3.2) | 3 | 24 (3.2) | 3 | 2 (2.6) | 0 |
| Abdominal pain | 29 (3.5) | 5 | 26 (3.5) | 5 | 3 (3.8) | 0 |
| ENT and eye symptoms | 198 (34.9) | 261 | 184 (34.7) | 220 | 14 (37.8) | 41 |
| Pharyngitis | 95 (11.6) | 7 | 90 (12.1) | 6 | 5 (6.5) | 1 |
| Conjunctivitis | 8 (1.0) | 5 | 8 (1.1) | 3 | 0 (0.0) | 2 |
| Acute rhinitis | 83 (13.9) | 230 | 76 (13.6) | 192 | 7 (17.5) | 38 |
| Acute anosmia | 52 (9.0) | 247 | 49 (9.1) | 211 | 3 (7.1) | 36 |
| Acute ageusia | 39 (6.7) | 249 | 38 (7.1) | 213 | 1 (2.4) | 36 |
| **Outcomes** | | | | |
| Hospitalisation | 195 (23.7) | 4 | 156 (20.9) | 3 | 39 (50.6) | 1 |
| Oxygen therapy | 96 (11.7) | 5 | 76 (10.2) | 5 | 20 (25.6) | 0 |
| Respiratory support | 32 (3.9) | 7 | 23 (3.1) | 7 | 9 (11.5) | 0 |
| Noninvasive ventilation (BIPAP, CPAP) | 16 (1.9) | 7 | 13 (1.7) | 7 | 3 (3.8) | 0 |
| High-flow nasal canula oxygen therapy | 5 (0.6) | 475 | 5 (1.5) | 416 | 0 (0.0) | 59 |
| Invasive ventilation | 12 (1.5) | 8 | 6 (0.8) | 8 | 6 (7.7) | 0 |
| ECMO | 4 (0.5) | 71 | 2 (0.3) | 67 | 2 (2.7) | 4 |
| Intensive care unit | 21 (2.5) | 2 | 13 (1.7) | 2 | 8 (10.3) | 0 |
| Death | 11 (1.4) | 16 | 7 (0.9) | 12 | 4 (5.4) | 4 |

Percentages were calculated on total numbers in each group (not on number of symptomatic patients/group). ENT: ear, nose and throat; BIPAP: bilevel positive airway pressure; CPAP: continuous positive airway pressure; ECMO: extracorporeal membrane oxygenation.
Statistics
Results are presented for all pwCF and by lung transplant status. Demographics and pre-infection CF characteristics and treatments are presented using descriptive statistics. Categorical variables are described as counts and percentages and continuous variables as median and interquartile range. Fisher exact test was used to compare the percentage of categorical variables between groups and Wilcoxon test was used to compare the median on continuous variables between groups.

The denominator for incidence was the ECFSPR population from 2018 [14] (2017 for France [15]). We evaluated the association of demographic and pre-infection clinical characteristics of pwCF with the symptoms and outcome of SARS-CoV-2 infection. Mixed effects univariable logistic regression analyses considered SARS-CoV-2 symptoms and outcomes as response variable and the characteristics of pwCF as explanatory variable (retaining variables with <30% missing data). A country random effect accounted for the effect of health systems. Odds ratios with 95% confidence intervals and p-values were calculated.

Variables with <5% missing data were included in multivariable logistic regression models to identify independent predictors of symptoms and outcomes. Moreover, models were only fitted when the number of events in the response variable was ≥5 times the number of predictor variables [16]. Adjusted OR with 95% CI and p-values were calculated. Data analysis was performed by ECFSPR statisticians, using SAS 9.4 and R 4.0.3 with the additional package geepack.

Results
Incidence
Of the 38 ECFSPR countries, 37 contributed information about SARS-CoV-2 infection in pwCF (figure 1).

SARS-CoV-2 infections occurred in two distinct waves, the first in March and April 2020 with a second larger wave from October to December 2020. The second wave was ongoing at the time of data cut-off (figure 2). As per our previous report, incidence varied widely by country (figure 3, supplementary Table 1).

Overall, 828 PCR-confirmed cases were reported from 26 countries, yielding an incidence of 17.2 per 1000 pwCF (95% CI: 16.0–18.4) (table 2). Incidence was significantly higher in lung-transplanted pwCF (28.6; 95% CI: 22.7–35.5) versus non-lung-transplanted pwCF (16.6; 95% CI: 15.4–17.8) (p<0.001).

Incidence increased along with age group (Fisher exact test; p<0.001) and was notably higher in all adult age groups compared to paediatric age groups. Similar trends were observed for non-lung-transplanted pwCF. In lung-transplanted pwCF, incidence did not vary notably between the age groups spanning 18–49 years; younger and older age groups had too few cases (<5) to allow comparison.

Demographics and CF characteristics
Of the 828 cases, 48.4% were male with a median age of 24 years (table 3). Most pwCF had normal body mass index (90.6%), pancreatic insufficiency (80.6%) and mild lung disease (59.9%). 26.1% had CF-related diabetes (CFRD) and 26.6% had chronic liver disease. Pre-infection medication use was common, and as expected for pwCF (table 3). The most frequent pulmonary infections were Staphylococcus aureus (57.7%) and Pseudomonas aeruginosa (43.4%).

Compared to non-lung-transplanted pwCF (n=750), lung-transplanted pwCF (n=78) were older and more frequently F508del homozygous. They had higher rates of pancreatic insufficiency, CFRD and systemic arterial hypertension. Concomitant medications also differed, due to different indications and medical needs.

Symptoms and outcomes of SARS-CoV-2 infection
SARS-CoV-2 infection gave rise to symptomatic illness in 75.7% of pwCF (81.7% in lung-transplanted pwCF versus 75.1% in non-lung-transplanted). Symptoms were most commonly general (64.8%), pulmonary (54.0%) and ENT and eyes (34.9%). The most common individual symptoms were fever (43.6%), increased cough (43.2%), fatigue (34.2%), myalgia/arthritis (22.4%) and pulmonary exacerbation (21.2%) (table 1).

Lung-transplanted pwCF had notably different rates of specific symptoms, with more frequent dyspnoea and respiratory failure and less frequent increased sputum and pulmonary exacerbation.
Of the 828 cases, 11.7% needed extra oxygen and 3.9% needed respiratory support, 23.7% were admitted to hospital and 2.5% to intensive care. Regretfully, 11 pwCF (1.4%) died. The case fatality rate was 1.4% (95% CI: 0.7–2.4). Demographic and baseline CF characteristics for the 11 pwCF who died are presented in supplementary Table 2.

FIGURE 2 Diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in people with cystic fibrosis (pwCF) (n=828) in 2020, by month.
Oxygen therapy, respiratory support and hospitalisation were >2-fold more common in lung-transplanted pwCF versus non-lung-transplanted; similarly, intensive care admission and death were 6-fold more common. In hospitalised patients, intensive care and death were around 2-fold more frequent in lung-transplanted pwCF versus non-lung-transplanted pwCF.

Factors associated with symptoms and worse outcomes

Univariable analyses are summarised in figure 4, with full results in supplementary Tables 3 and 4.

| Age group years | Total | Non-lung transplant | Lung transplant |
|-----------------|-------|---------------------|-----------------|
|                 | Cases | CF population       | Incidence per 1000 (95% CI) | Cases | CF population | Incidence per 1000 (95% CI) | Cases | CF population | Incidence per 1000 (95% CI) |
| Total           | 828   | 48,211              | 17.2 (16.0–18.4)          | 750   | 45,266         | 16.6 (15.4–17.8)          | 78    | 27,290         | 28.6 (22.7–35.5)          |
| 0–11            | 134   | 17,179              | 7.8 (6.5–9.2)             | 134   | 17,100         | 7.8 (6.6–9.3)             | 0     | 13             | 0.0 (0.0–247.1)           |
| 12–17           | 113   | 7,396               | 15.3 (12.6–18.3)          | 111   | 7,278          | 15.3 (12.6–18.3)          | 2     | 84             | 23.8 (2.9–83.4)           |
| 18–29           | 291   | 12,162              | 23.9 (21.3–26.8)          | 268   | 11,286         | 23.7 (21.0–26.7)          | 23    | 816            | 28.2 (17.9–42)            |
| 30–39           | 164   | 6,493               | 25.3 (21.6–29.4)          | 135   | 5,445          | 24.8 (20.8–29.3)          | 29    | 1,014          | 28.6 (19.2–40.8)          |
| 40–49           | 87    | 3,280               | 26.5 (21.3–32.6)          | 67    | 2,679          | 25.0 (19.4–31.7)          | 20    | 583            | 34.3 (21.1–52.5)          |
| ≥50+            | 39    | 1,701               | 22.9 (16.4–31.2)          | 35    | 1,478          | 23.7 (16.5–32.8)          | 4     | 219            | 18.3 (5.0–46.1)           |

All cases of SARS-CoV-2 in pwCF and the general population were PCR-confirmed. Incidence was calculated as (SARS-CoV-2 cases/number of people in the population) × 1000. CF population size was from the 2018 European Cystic Fibrosis Society Patient Registry report (2017 for France).
| TABLE 3 | Demographics and pre-infection characteristics of people with cystic fibrosis (CF) |
|-----------------|---------------------------------|-----------------|-----------------|
|                | Total                          | Non-lung transplant | Lung transplanted* |
|                | n (%)                          | Missing            | n (%)            |
|                | Missing                        | Missing            | Missing         |
| Subjects n     | 828                            | 750                | 78               |
| Sex            |                                 |                    |                  |
| Female         | 427 (51.6)                     | 384 (51.2)         | 43 (55.1)        |
| Male           | 401 (48.4)                     | 366 (48.8)         | 35 (44.9)        |
| Median age years | 24.0                          | 0                  | 23.0             | 0 | 34.5 |
| 0–11 years     | 134 (16.2)                     | 134 (17.9)         | 0 (0)            |
| 12–17 years    | 113 (13.6)                     | 111 (14.8)         | 2 (2.6)          |
| 18–29 years    | 291 (35.1)                     | 268 (35.7)         | 23 (29.5)        |
| 30–39 years    | 164 (19.8)                     | 135 (18.0)         | 29 (37.2)        |
| 40–49 years    | 87 (10.5)                      | 67 (8.9)           | 20 (25.6)        |
| ≥50 years      | 39 (4.7)                       | 35 (4.7)           | 4 (5.1)          |
| CFTR genotype  |                                 |                    |                  |
| F508del/F508del | 218 (26.3)                   | 180 (24.0)         | 38 (48.7)        |
| F508del/other  | 262 (31.6)                     | 236 (31.5)         | 26 (33.3)        |
| Other/Other    | 348 (42)                       | 334 (44.5)         | 14 (17.9)        |
| BMI, z-score+  |                                 |                    |                  |
| < −2           | 54 (7.1)                       | 40 (5.8)           | 14 (18.7)        |
| −2 –2          | 692 (90.6)                     | 631 (91.6)         | 61 (81.3)        |
| >2             | 18 (2.4)                       | 18 (2.6)           | 0 (0)            |
| Lung disease FEV1 % pred§ | 28 | 26 | 2 |
| Severe (<40)   | 76 (10.3)                      | 65 (9.8)           | 11 (14.5)        |
| Moderate (>40–70) | 221 (29.9)                   | 206 (31.0)         | 15 (19.7)        |
| Mild (>70)     | 443 (59.9)                     | 393 (59.2)         | 50 (65.8)        |
| Pancreatic insufficiency | 660 (80.6)                               | 584 (78.8)         | 9 76 (97.4) 0 |
| CF-related diabetes | 206 (26.1)               | 153 (21.4)         | 34 53 (72.6) 5 |
| ABPA           | 47 (7.3)                       | 41 (6.9)           | 158 6 (12.5) 30 |
| Chronic liver GI disease | 163 (26.6)                   | 148 (26.7)         | 196 15 (25.4) 19 |
| Systemic arterial hypertension | 32 (5.1)                 | 20 (3.4)           | 156 12 (34.3) 43 |
| Treatment      |                                 |                    |                  |
| CFTR modulator therapy | 260 (31.5)                       | 260 (34.8)         | 2 (0.0)          |
| Ivacaftor      | 43 (5.2)                       | 43 (5.7)           | 0 (0.0)          |
| Lumacaftor     | 72 (8.7)                       | 72 (9.6)           | 0 (0.0)          |
| Tezacaftor     | 75 (9.1)                       | 75 (10.0)          | 0 (0.0)          |
| Elexacaftor/Tezacaftor | 63 (7.6)                  | 63 (8.4)           | 0 (0.0)          |
| Yes, type unknown | 4 (0.5)                     | 4 (0.5)            | 0 (0.0)          |
| Yes, other     | 3 (0.4)                        | 3 (0.4)            | 0 (0.0)          |
| Inhaled antibiotics | 332 (50.7)                    | 313 (50.6)         | 131 19 (52.8) 42 |
| Oral antibiotics | 234 (38.5)                    | 215 (37.3)         | 174 19 (59.4) 46 |
| Inhaled steroid | 318 (42.0)                    | 302 (43.7)         | 59 16 (24.2) 12 |
| Azithromycin   | 307 (48.1)                     | 253 (34.7)         | 21 54 (70.1) 1 |
| DNase          | 382 (58.3)                     | 377 (60.9)         | 131 5 (13.9) 42 |
| Hypertonic saline | 338 (51.4)                  | 334 (53.8)         | 129 4 (11.1) 42 |
| Flu vaccine    | 207 (57.8)                     | 180 (55.6)         | 426 27 (79.4) 44 |
| Microbiology   |                                 |                    |                  |
| Pseudomonas aeruginosa | 346 (43.4)                | 313 (42.6)         | 15 33 (53.2) 16 |
| Staphylococcus aureus | 420 (57.7)                     | 403 (59.0)         | 67 17 (37.8) 33 |
| Burkholderia cepacia complex | 29 (4.4)                | 28 (4.5)           | 122 1 (3.1) 46 |
| MRSA           | 65 (9.3)                       | 63 (9.5)           | 84 2 (5.6) 42 |
| Non-tuberculous mycobacteria | 28 (5.2)                | 28 (5.5)           | 242 0 (0.0) 50 |
| Stenotrophomonas maltophilia | 65 (8.8)                | 63 (9.1)           | 61 2 (4.1) 29 |
| Achromobacter species | 60 (8.1)                   | 54 (7.8)           | 61 6 (12.0) 28 |
| Aspergillus colonization | 102 (14.0)               | 99 (13.8)          | 71 8 (16.0) 28 |

CFTR: cystic fibrosis transmembrane conductance regulator; BMI: body mass index; FEV1: % pred: per cent predicted forced expiratory volume in 1 s; ABPA: allergic bronchopulmonary aspergillosis; GI: gastrointestinal; Iva: ivacaftor; Lum: lumacaftor; Tez: tezacaftor; Elexa: elexacaftor; MRSA: methicillin-resistant Staphylococcus aureus. #: 10 recipients of other solid organ transplants were included in this group (7 liver, 2 kidney, 1 unspecified). ¶: percentages are computed excluding missing data. +: BMI z-score was only calculated for patients aged 2 years and over, using Centers for Disease Control and Prevention reference values [40]. §: FEV1 % pred was only calculated for patients aged 2 years and over.
Multivariable models were fitted including only variables with <10% missing data and for response variables with sufficient events (any symptoms, pulmonary symptoms, general symptoms, hospitalisation, and oxygen therapy). No significant interactions existed between predictor variables and lung transplant in any of the multivariable models, meaning that risk factors have similar effects in non-lung-transplanted and lung-transplanted pwCF. Therefore, we present multivariable analyses for all 828 pwCF with SARS-CoV-2 infection.

Factors associated with symptoms of SARS-CoV-2 infection were age >40 years, any F508del mutation, and taking pancreatic enzymes (figure 5). General symptoms and pulmonary symptoms were associated with any F508del mutation. Pulmonary symptoms were also associated with age ≥18 years. Additionally, use of cystic fibrosis transmembrane conductance regulator (CFTR) modulators tended towards protecting against general symptoms (p=0.058) (supplementary Table 5).

Regarding outcomes, lung transplant, CFRD, moderate and severe lung function as well as azithromycin use (often considered surrogate marker for *P. aeruginosa* infection and worse lung function) were significantly associated with hospitalisation and oxygen therapy (figure 5 and supplementary Table 6). Age 18–29 years versus <18 years was negatively associated with oxygen therapy, and CFTR modulator use was negatively associated with hospitalisation. Although multivariable models could not be fitted for the outcome death, nine out of 11 pwCF who died and had complete information available had at least one risk factor for hospitalisation and/or oxygen therapy (information was incomplete for two adult pwCF).
Discussion

In this report we estimate the incidence of SARS-CoV-2 infection in pwCF in Europe to be 17.2/1000 pwCF in the year up to December 31, 2020. This is markedly higher than previous estimates of 0.7 to 4.1/1000 pwCF from earlier publications covering the first wave of the pandemic (data cut-offs before July 2020) [7, 8, 10, 11], although it is similar to an Italian estimate of 15.8/1000 pwCF up to November 2020 [12]. The data collected covers the 38 countries reporting to the ECFSPR and involves a cohort of 828 pwCF who were PCR positive for SARS-CoV-2. We also present risk factors for symptoms and worse outcomes of SARS-CoV-2 infection.

Infections between February and June 2020 (wave 1) were concentrated in Western Europe. The second wave (July to December 2020) extended towards the east and south, with higher peaks of infections. The much higher incidence in pwCF after summer 2020 reflects increased incidence in the general European population after summer 2020, which is only partly explained by different testing strategies and public restrictions [17]. Nevertheless, we probably underestimate incidence due to the voluntary nature of case reporting, burdened healthcare staff and low ECFSPR coverage (including <80% of patients) in some countries (Armenia, Belarus, Bulgaria, Lithuania, Poland, Romania, Spain, Turkey and Ukraine). Selection bias towards voluntary reporting of more severe cases cannot be excluded.

Incidence was notably higher in lung-transplanted versus non-lung-transplanted pwCF (28.6 versus 16.6/1000 pwCF). Interestingly, the fold increase in incidence between the first and second waves was considerably lower for lung-transplanted pwCF compared to non-transplanted pwCF (1.4-fold versus 3.8-fold, respectively). This could be due to different testing rates in the two populations, or sustained...
guidance that transplanted people continue highly vigilant shielding and hygiene, while non-transplanted pwCF might have resumed more activities after June [18].

Confirming our earlier report [7], around three-quarters of pwCF and SARS-CoV-2 infection had symptomatic illness, lower than earlier reports from smaller CF studies (82–100%) [8, 10, 11] but similar to rates in the general population [19]. Again, this may reflect differing availability and strategy of testing different patient groups and the general population over time and between countries. The true rates of incidence, as well as asymptomatic infection, can only be determined by systematic wide-scale testing of all pwCF, either in a trial or as part of routine care.

We found that pwCF mostly had general and pulmonary symptoms, as also reported in a French study [11]. Some of the most frequent symptoms of SARS-CoV-2 infection reported here are common features of CF (increased cough and pulmonary exacerbation), some less so (fever, myalgia/arthralgia). Ageusia and anosmia were uncommon symptoms in pwCF in this report (<10%) and previous CF reports [9, 11], compared to the general population (38% and 41%, respectively [20]). These surprisingly low rates may be due to high levels of missing data for these symptoms, under-reporting or concomitant sinus disease, a regular feature in CF. Of note, 71.5% of pwCF demonstrated impaired smell in a small 2012 study [21].

Factors associated with symptomatic SARS-CoV-2 infection in pwCF were age >40 years, any F508del mutation and pancreatic insufficiency, indicating that older individuals with “classic” CF might be more prone to become symptomatic than younger pwCF with milder CFTR mutations.

Lung-transplanted pwCF had slightly higher rates of SARS-CoV-2 symptoms compared to other pwCF, confirming previous observations [8]. Transplanted individuals more often had increased dyspnoea and respiratory failure, but lower rates of increased sputum and pulmonary exacerbation, which is in line with differing lung disease phenotypes transplanted and non-transplanted pwCF.

The case fatality rate of SARS-CoV-2 infection in pwCF dropped from 3.85% up to June 30, 2020 [7] to 1.4% up to December 31, 2020, despite the higher numbers of infections during the second wave. Likewise, markedly fewer pwCF and SARS-CoV-2 infection required oxygen therapy, respiratory support, hospitalisation and intensive care in wave 2 versus wave 1. This mirrors decreased rates of intensive care and death in the general population [22] and could reflect improved management of severe cases of SARS-CoV-2 infection based on clinical experience and trials such as RECOVERY [23]. In CF, clinicians may have reduced precautionary hospitalisations and even intensive care admissions in favour of a more “watch and wait” approach to care, reassured by the observations that SARS-CoV-2 has a less severe impact on pwCF than initially expected. The fascinating but currently theoretical hypothesis that CFTR dysfunction may protect against SARS-CoV-2 replication in pwCF needs further investigation [24].

Solid organ transplant recipients are at increased risk of severe outcomes upon SARS-CoV-2 infection, including hospitalisation and intensive care [25–28]. In our cohort, lung transplant was associated with hospitalisation and oxygen therapy. In previous studies, lung-transplanted pwCF were more frequently treated and hospitalised [7, 8, 11]; our multivariable analysis confirms these descriptive findings in a substantial cohort of 828 pwCF. This supports recommendations that solid organ transplant recipients are vaccinated against SARS-CoV-2. Reduced antibody response to the first mRNA vaccine dose in people after lung transplant was reported recently; however, a final conclusion on vaccination success cannot be drawn from these preliminary data and vaccination against SARS-CoV-2 continues to be strongly recommended for transplanted individuals [29].

Moderate and severe lung disease and long-term azithromycin (often considered a surrogate for worse lung disease) were also associated with hospitalisation and additional oxygen use. Moderate–severe lung disease (ppFEV1<70) was also associated with hospitalisation in univariable analyses in a previous global study in pwCF [8].

Azithromycin was proposed as a possible therapy for coronavirus disease 2019 (COVID-19) but did not improve outcomes in the RECOVERY trial [30]. Our finding suggesting an adverse effect of long-term azithromycin use on SARS-CoV-2 outcome should be interpreted cautiously. Azithromycin has different indications in non-transplanted and transplanted pwCF, and results cannot be compared for these groups. Also, azithromycin is often considered as a surrogate for chronic P. aeruginosa infection and severe lung disease [31, 32], and therefore cannot be counted as an independent variable in our multivariable analysis. This contributes to a strong indication bias for azithromycin, where pwCF treated with azithromycin appear to have worse outcomes. Analysing matched groups of azithromycin users and non-users could overcome
this bias [33]; however, this is uneconomic in our analysis. Protopathic bias could also exist for azithromycin, whereby preferential treatment of sicker patients seems to reverse cause and effect, suggesting that the treatment is associated with weakening disease. Overall, we must be cautious not to over-interpret azithromycin treatment as a risk factor for a more severe SARS-CoV-2 outcome. The identification of more advanced lung disease as a risk factor for worse outcomes supports our previous advice that pwCF need to protect their lung health by adhering to medication and physiotherapy regimens and exercise.

CFRD, reported for 26.1% pwCF in our cohort, was associated with hospitalisation and oxygen therapy, although not with symptoms. In an earlier study, hospitalisation was more frequent in pwCF with CFRD, although oxygen use was less frequent [8]. Diabetes Type 1 and 2 is an established risk factor for severe outcomes with SARS-CoV-2 infection [34], but CFRD differs in mechanism and clinical impact [35]. Indeed, CFRD prevalence increases with age and could be considered as a proxy for advanced CF (creating the same potential bias as azithromycin, discussed above). Nonetheless, good control of CFRD is essential for overall health, and telehealth clinics can help pwCF and CFRD to maintain good glycaemic control during the pandemic [36].

Male sex is a risk factor for severe outcomes and death in SARS-CoV-2 [37, 38]. In our cohort, male sex was slightly underrepresented (48.4%) and not associated with symptoms or adverse outcomes. Female pwCF have a more severe clinical course of CF, culminating in younger median age at death [39]. It is possible that in our cohort the risk of worse SARS-CoV-2 outcomes in males is offset by a worse outcome for female pwCF. Further studies need to confirm this hypothesis.

Multivariable analyses in non-transplanted pwCF yielded similar risk factors. ppFEV1 <70 and long-term azithromycin were associated with hospitalisation and additional oxygen use, and CFRD was associated with hospitalisation only. Altogether, these results indicate that the relevant risk factors for severe SARS-CoV-2 disease in pwCF are CFRD, lung transplantation and more advanced lung disease.

We discussed the limits of our registry-based multinational data collection in depth previously [7]. Limitations specific to the multivariable analysis include lack of context around some demographic and baseline CF characteristics. For example, the exact duration of comorbidities and concomitant medications are unknown. Some variables had high rates of missing data, due to differences in data available from national registries. Importantly, the demographic and pre-infection CF characteristics could have dated from the registry collection of the previous calendar year, depending on when SARS-CoV-2 infection occurred. Finally, SARS-CoV-2 incidence may be underestimated due to incomplete surveillance and voluntary reporting bias towards severe cases and because many mild and asymptomatic cases probably went undiagnosed. Thus, we may have overestimated severity. Similarly, surveillance for SARS-CoV-2 infection may have been more complete in certain groups than others, based on previous reports of risk factors (e.g., male sex, transplant, etc. in the general and CF populations). Without a good understanding of surveillance rates, comparisons of incidence between different groups should be interpreted with caution. Prospective data collection on SARS-CoV-2 infection in pwCF in Europe is ongoing, and aims to enhance understanding, prevention and treatment of SARS-CoV-2 infection in pwCF. Future work includes long-term follow-up of lung function in patients with SARS-CoV-2 versus the wider CF population, and follow-up of incidence and severity following vaccination. In future, we may need to include cases diagnosed by antigen lateral flow test only, as many countries now accept a positive result as definitive, without confirmatory PCR. In addition, ECFSPR works closely together with a large global CF registry group to further improve our knowledge on SARS-CoV-2 in pwCF worldwide.

In summary, we report the first prospective study in a large cohort of pwCF infected with SARS-CoV-2 in Europe during the pandemic until the end of 2020. Clinical symptoms in pwCF are highly variable, and pulmonary symptoms resemble those from a CF exacerbation. We identified lung transplantation, CFRD and moderate to severe lung disease as independent risk factors for severe outcome after SARS-CoV-2 infection. All pwCF should maintain protective measures to prevent SARS-CoV-2 infection and be vaccinated against SARS-CoV-2. In particular, we strongly recommend that pwCF with lung transplants, ppFEV1 <70% predicted and/or CFRD shield more vigorously and be prioritised for vaccination.

Acknowledgements: We thank the people with CF, and their families, for consenting to their data being included in the ECFSPR. We thank the centres and individual country representatives for allowing the use of the anonymised patient data.

https://doi.org/10.1183/23120541.00411-2021
Provenance: Submitted article, peer reviewed.

Collaborators: We would like to thank the people who provided the data and the members of the ECFSPR Scientific Committee. Austria: Sabine Burghart and Andrea Lakatos-Krepcic, Abteilung für Atmungs- und Lungenerkrankungen, Krankenhaus Hietzing, Vienna, Austria; Johannes Eder, Zertifiziertes CF-Zentrum für Kinder und Erwachsene, Medizinische Universität Innsbruck, Innsbruck, Austria; Katharina Kainz, Abteilung für Kinder- und Jugendheilkunde mit Ambulanz, Wilhelminalspital, Vienna, Austria; Margit Kallinger and Monika Pell, Abteilung für Kinder- und Jugendheilkunde und Abteilung für Lungenheilkunde, Landeskrankenhaus Steyr, Austria; Marta Mozdzzen, Abteilung für Lungenkrankheiten, Klinikum Wels-Grieskirchen, Wels, Austria; Sabine Renner, Klinik für Kinder- und Jugendheilkunde, Cystische Fibrose Ambulanz, Medizinische Universität Wien, Vienna, Austria; Martin Stadlinger, Klinik für Lungenheilkunde/ Pneumologie, Kepler Universitäts Klinikum, Linz, Austria; Christina Thir, Univ. Klinik für Kinder- und Jugendheilkunde, Kepler Universitätssklinikum, Linz, Austria. Belarus: Svetalana Keeegan, Belarusian Republican Children’s Center of Pulmonology and Cystic Fibrosis, Pulmonary Department, 3rd City Children’s Clinical Hospital, Minsk, Belarus. Belgium: Hedwige Boboli, Department of Pediatrics, Pediatric Pulmonology, University Hospital Liège, Liège, Belgium; Elke De Wachter, Department of Paediatric Pulmonology, Universitair ziekenhuis Brussel, Brussels, Belgium; Lieven Dupont, Department of Pneumology, University Hospitals Leuven, Leuven, Belgium; Sophie Gohy, Department of Pulmonology Cliniques Universitaires Saint-Luc UCL, and Cystic Fibrosis Reference Center Cliniques Universitaires Saint-Luc UCL, Brussels, Belgium; Laurence Hanssens, CF Centre, Hôpital Universitaire des Enfants Reine Fabiola (HUDERF), and Institut de mucoviscidose de l’université libre de Bruxelles (ULB), hôpital universitaire des enfants Reine Fabiola – ULB, Brussels, Belgium; Christiane Knoop, Institut de mucoviscidose de l’université libre de Bruxelles (ULB), hôpital universitaire Erasme – ULB, Brussels, Belgium; Elise Lammertijn (on behalf of the scientific committee), Cystic Fibrosis Europe, and Association Muco A.S.B.L. – Mucovereniging V.Z.W., Brussels, Belgium; Vicky Nowé, Dept of Pulmonology, GZA Sint-Vincentius Hospital, Antwerp, Belgium; Jessica Pirson, Service de Pneumologie, CHR Citadelle, Liège, Belgium; Matthieu Thimmesch, Service de Pédiatrie, CHC Clinique du MontLéger, Liège, Belgium; Eva Van Braeckel, Cystic Fibrosis Reference Centre, Dept of Respiratory Medicine, Ghent University Hospital, and Dept of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium; Kim Van Hoorebeek, Dept of Pediatrics, Antwerp University Hospital, Edegem, Belgium; Eef Vanderhelst, Respiratory Division, University Hospital UZ Brussel, Brussels, Belgium. Croatia: Duška Tješić-Drinčević and Ivan Bambir, University Hospital Centre Zagreb, Cystic Fibrosis Centre – Paediatrics and Adults, Zagreb, Croatia. Czech Republic: Alena Bilkova, Cystic Fibrosis Centre, Dept of Pneumology, Dept of Preventive Care, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic; Macek Milan Jr (on behalf of the scientific committee), Dept of Biology and Medical Genetics, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic. Denmark: Tania Pressler, Copenhagen Cystic Fibrosis Centre, Rigshospitalet, Copenhagen, Denmark. France: Pierre-Régis Burgel, Respiratory Medicine and National Cystic Fibrosis Reference Center, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Université de Paris, Institut Cochin, INSERM U1016, Paris, France; Lydia Lemonnier-Videau, Vaincre la Mucoviscidose, Paris, France. French Cystic Fibrosis Reference Network study group: Michel Abely, Centre Hospitalier Universitaire de Reims, Reims, France; Carole Bailly Piccini, Centre Hospitalier Universitaire de Limoges, Limoges, France; Muriel Laurans, Centre Hospitalier Universitaire de Caen, Caen, France; Sandra De Miranda, Hôpital Foch, Suresnes, France; Eric Deneuville, Centre Hospitalier Universitaire de Rennes, Rennes, France; Bertrand Clochéville, Centre Hospitalier Universitaire de Tours – Clochéville Hospital, Tours, France; Marie-Laure Dalphin, Centre hospitalier universitaire de Besançon, Besançon, France; Isabelle Danner Boucher, Centre Hospitalier Universitaire de Nantes, Nantes, France; Sabine Burghart and Andrea Lakatos-Krepcic, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand France; Raphael Chiron, Centre Hospitalier Universitaire de Montpellier, Montpellier, France; Emmanuelle Corrier Duet, Centre Hospitalier de Versailles, Le Chesnay-Rocquencourt, France; Laure Cosson, Centre Hospitalier Régional Universitaire de Tours – Clochéville Hospital, Tours, France; Marie-Laure Dalphin, Centre hospitalier universitaire de Besançon, Besançon, France; Isabelle Danner Boucher, Centre Hospitalier Universitaire de Nantes, Nantes, France; Sandra De Miranda, Hôpital Foch, Suresnes, France; Eric Deneuville, Centre Hospitalier Universitaire de Rennes – Hôpital Sud, Rennes, France; Chantal Belleguic, Centre Hospitalier Universitaire de Rennes – Hôpital Pontchaillou, Rennes, France; Tiphaine Bihouée, Centre Hospitalier Universitaire de Nantes, Nantes, France; Yves Billon, Centre Hospitalier Régional Universitaire de Nancy, Nancy, France; Stéphanie Bui, Centre Hospitalier Universitaire Bordeaux, Bordeaux, France; Boubou Camara, Centre Hospitalier Universitaire de Grenoble, La Tronche, France; Marie-Christine Cheraud, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand France; Raphael Chiron, Centre Hospitalier Universitaire de Montpellier, Montpellier, France; Emmanuelle Corrier Duet, Centre Hospitalier de Versailles, Le Chesnay-Rocquencourt, France; Laure Cosson, Centre Hospitalier Régional Universitaire de Tours – Clochéville Hospital, Tours, France; Marie-Laure Dalphin, Centre hospitalier universitaire de Besançon, Besançon, France; Isabelle Danner Boucher, Centre Hospitalier Universitaire de Nantes, Nantes, France; Sandra De Miranda, Hôpital Foch, Suresnes, France; Eric Deneuville, Centre Hospitalier Universitaire de Rennes – Hôpital Sud, Rennes, France; Jean-Christophe Dubus, Hôpitaux Universitaires de Marseille, Marseille, France; Isabelle Durieu, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France; Ralph Epuard, Hôpital Intercommunal de Crétel, Créteil, France; Michèle Gerardin, AP-HP - Hôpital Robert-Debré, Paris, France; Dominique Grenet, Hôpital Foch, Suresnes, France; Véronique Houdouin, AP-HP - Hôpital Robert-Debré, Paris, France; Frédéric Huet, Centre Hospitalier Universitaire de Dijon Bourgogne, Dijon, France; Kanaan Reem, AP-HP Hôpital Cochin, Paris, France; Romain Kessler, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; Jeanne Languepin, Centre Hospitalier Universitaire de Limoges, Limoges, France; Muriel Laurans, Centre Hospitalier Universitaire de Caen, Caen, France; Sylvie Leroy, Centre Hospitalier Universitaire de Nice, Nice, France; Cathie Llerena, Centre Hospitalier Universitaire de Grenoble, La Tronche, France; Julie Macey, Centre Hospitalier Universitaire de Bordeaux – Hôpital Haut-Lévêque, Pessac, France; Julie Mankikian, Centre Hospitalier Régional Universitaire de Tours – Bretonneau, Tours, France; Christophe Marguet, Centre Hospitalier Universitaire de Rouen, Rouen, France; Clémence Martin, AP-HP Hôpital Cochin, Paris, France; Laurent Mely, Hospices Civils de Lyon – Hôpital Renée Sabran, Giens-Hyères, France; Marie Mittaine, Centre Hospitalier Universitaire de Toulouse – Hôpital des Enfants, Toulouse, France;
Fibrosis Center, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Israel; Galit Livnat, Carmel CF Center, Technion-Israel Institute of Technology, Haifa, Israel. Italy: Annalisa Amato and Gianluca Ferrari, technical board of ICFR, Italian Cystic Fibrosis Ligue, Rome, Italy; Raffaele Badolato and Piercarlo Poli, Department of Pediatrics, Regional support Centre for Cystic Fibrosis, Children’s Hospital – ASST Spedali Civili Pz. le Spedali Civili, University of Brescia, Brescia, Italy; Fiorella Battistini and Valentina Donati, CF Referral Center Emilia-Romagna Region, Cesena, Italy; Elisabetta Bignamini and Anna Folino, CF Referral Center Piemonte and Valle D’Aosta Regions, Ospedale Infantile Regina Margherita – Sant’ Anna, Turin, Italy; Vincenzo Carnovale, Adult CF Referral Center Campania Region, Naples, Italy; Carlo Castellani and Rosaria Casciaro, CF Referral Center Liguria Region, IRCCS Istituto Giannina Gaslini Genova, Genoa, Italy; Giuseppe Cimino, CF Referral Center Lazio Region, Rome, Italy; Marco Cipolli and Francesca Lucca, CF Referral Center Veneto Region, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy; Mirella Collura and Francesca Ficili, CF Referral Center Sicily Region, Palermo, Italy; Valeria Daccò, Vanessa Gagliano and Giovanna Pizzamiglio, CF Referral Center Lombardia Region, Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico, Milan, Italy; Valeria Mencarini and Nicola Palladino, CF Referral Center Umbria Region, Gubbio, Italy; Salvatore Leonardi and Novella Rotolo, CF Support Center Sicily Region, Catania, Italy; Maria Cristina Lucanto and Ester Quattromano, CF Referral Center Sicily Region, Messina, Italy; Vincenzina Lucidi, Fabio Majo, Federico Alghisi and Fabiana Ciciriello, CF UOC, Paediatric Hospital “Bambino Gesù”, Rome, Italy; Antonio Manca and Giuseppina Leonetti, CF Referral Center Puglia Region, Bari, Italy; Massimo Maschio, CF Referral Center Friuli-Venezia Giulia Region, IRCCS Materno Infantile Burlo Garofolo, Trieste, Italy; Barbara Messore, Adult CF Centre Torino, Pulmonology Dept, Azienda Ospedaliero Universitaria San Luigi Gonzaga, Orbassano, Italy; Stefano Pantano, CF Referral Center Abruzzo and Molise Region, Teramo, Italy; Giovanni Pisi and Cinzia Spaggiari, CF Referral Center Emilia-Romagna Region, Parma, Italy; Valeria Raia and Caterina Laezza, CF Pediatric Referral Center Campania Region, Naples, Italy; Mirco Ros, Veneto Region CF Support Center of Treviso, Ospedale Ca’ Foncello, Treviso, Italy; Donatello Salvatore, Cystic Fibrosis Center, Hospital San Carlo, Potenza, Italy; Marco Salvatore, Undiagnosed Rare Diseases Interdepartmental Unit, National Center Rare Diseases, Istituto Superiore di Sanità, Rome, Italy; Giovanni Taccetti and Michela Francalanci, Cystic Fibrosis Center, Toscana Region, Florence, Italy; Pamela Vitullo, CF Support Center Puglia Region, Cerignola, Italy. Luxembourg: Hélène De la Barrière, Department of Pulmonology, Hôpitaux Robert Schuman, Luxembourg, Luxembourg. The Netherlands: Josje Altenburg, Dept of Pulmonology, Amsterdam University Medical Center, The Netherlands; Michiel Bannier, Dept of Pediatric Pulmonology, University Medical Center Maastricht, The Netherlands; Harry Heijerman, Dept of Pulmonology, University Medical Center Utrecht, The Netherlands; Hettie Janssens, Dept of Pediatric Pulmonology, Erasmus Medical Center Rotterdam, The Netherlands; Gerard Koppelman, Dept of Pediatric Pulmonology, University Medical Center Groningen, The Netherlands; Renske van der Meer, Dept of Pulmonology, Haga Ziekenhuis Den Haag, The Hague, The Netherlands; Peter Merkus, Dept of Pediatric Pulmonology, Radboud University Medical Center Nijmegen, The Netherlands; Jacquelyn Noordhoek, NCFS, Baarn, The Netherlands; Marianne Nuijsink, Department of Pediatric Pulmonology, Haga Ziekenhuis Den Haag, The Hague, The Netherlands; Suzanne Terheggen, Dept of Pediatric Pulmonology, Amsterdam University Medical Center, The Netherlands; Hester van der Vaart, Dept of Pulmonology, University Medical Center Groningen, The Netherlands; Geert-Jan Wesseling, Dept of Pulmonology, University Medical Center Maastricht, The Netherlands; Karin de Winter, Dept of Pediatric Pulmonology, University Medical Center Utrecht, The Netherlands; Domenique Zomer-van Ommen, NCFS, Baarn, The Netherlands. North Macedonia: Tatjana Jakovska Maretti, Center for Cystic Fibrosis, Children and Adults, Institute for Respiratory Diseases in Children, Kozle, North Macedonia. Norway: Anita Santad whiteh, Norwegian Cystic Fibrosis Registry, Oslo, Norway. Portugal: Adelina Amorim, Centro Hospitalar S. João, Pulmonology Dept, Porto, Portugal; Fabienne Gonçalves, Centro Hospitalar do Porto Materno-Infantil, Porto, Portugal; Sónia Silva, Dept of Pediatrics, Centro Hospitalar Universitário de São João, Porto, Portugal. Russia: Elena Amelina, Cystic Fibrosis Dept, Scientific Research Institute of Pulmonology of the Federal Medical and Biological Agency of Russia, Moscow, Russian Federation; Evgeniya Boitsova, Department of Propaedeutics of Children’s Diseases, Federal State Budgetary Scientific Institution of Higher Education “Saint Petersburg state pediatric medical University” of the Russian Federation Ministry of Health, Saint Petersburg, Russia; Yuliya Gorinova, National Medical Research Center for Children’s Health, Moscow, Russia; Stanislav Krasovsky, Laboratory of Cystic Fibrosis, Scientific Research Institute of Pulmonology of the Federal Medical and Biological Agency of Russia, Moscow, Russia; Maria Mukhina, Medical and Genetic Dept, Cystic Fibrosis Office of the State Budgetary Healthcare Institution “Morozovskaya Children’s Municipal Clinical Hospital” Moscow, Russia; Victoria Sherman, The Scientific and Clinical Dept of Cystic Fibrosis, Research Centre for Medical Genetics, Moscow, Russia; Olga Simonova, National Medical Research Center for Children’s Health, Morozov State Pediatric Teaching Hospital, Moscow Healthcare Dept, I.M. Sechenov First Moscow State Medical University (Sechenov University), Healthcare Ministry of Russia, Moscow, Russian Federation; Nataliya Kharsishkaya, Laboratory of Genetic Epidemiology, “Research Centre for Medical Genetics”, Moscow, Russian Federation; Elena Zhekaite, Dept of Cystic Fibrosis, “Research Centre for Medical Genetics”, Moscow, Russian Federation. Slovakia: Eva Bérešová, Centrum cystické fibrozy pre dospelých FNSP FDR, Banská Bystrica, Slovakia; Nina Bilíňaková, pracovisko Podunajské Biskupice, Klinika detské pneumologie SZU UN Bratislava, Bratislava, Slovakia. Slovenia: Julij Šeb, University Clinic of Pulmonary and Allergic Diseases, Golnik, Slovenia. Spain: Antonio Alvarez Fernández, Adult Cystic Fibrosis unit,
Conflict of interest: A. Jung has nothing to disclose. A. Orenti has nothing to disclose. F. Dunlevy reports support for the present manuscript from Chiesi Farmaceutici SpA. E. Aleksejeva has nothing to disclose. E. Bakkeheim has
nothing to disclose. V. Bobrownichy has nothing to disclose. S.B. Carr reports receiving speaker honoraria from Vertex and Chiesi, outside the submitted work; participation on a Data Safety Monitoring Board or Advisory Board for Vertex, Profile Pharma and Chiesi, outside the submitted work; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid from UK CF Trust; PI for Pharmacovigilance study, payment to institution from Pharmaxis, outside the submitted work. C. Colombo has nothing to disclose. H. Corvol has nothing to disclose. R. Cosgrif declares outside the submitted work to be the director of the Cystic Fibrosis Trust. G. Daneau has nothing to disclose. D. Dogru has nothing to disclose. P. Drevinek reports grants or contracts from Ministry of Health, Czech Republic, outside the submitted work; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Vertex Pharmaceuticals and Actelion Pharmaceuticals, outside the submitted work; participation on a Data Safety Monitoring Board or Advisory Board for Vertex Pharmaceuticals, outside the submitted work; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid from Society for Medical Microbiology, outside the submitted work. A.D. Vukic has nothing to disclose. I. Fajac reports grants or contracts from Boehringer Ingelheim, Celtaxsys, Corbus Pharmaceuticals, and Vertex Pharmaceuticals, outside the submitted work; consulting fees from Boehringer Ingelheim and Vertex Pharmaceuticals, outside the submitted work; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Vertex Pharmaceuticals and Boehringer Ingelheim, outside the submitted work; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid for European Cystic Fibrosis Society. A. Fox support for the present manuscript from Chiesi Farmaceutici SpA. S. Fustik has nothing to disclose. V. Gulmans has nothing to disclose. S. Harutyunyan has nothing to disclose. E. Hatzigiorgou has nothing to disclose. I. Kasi has nothing to disclose. H. Kayserová has nothing to disclose. E. Kondratyeva reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from All-Russian online school with international participation, outside the submitted work. U. Krivec has nothing to disclose. H. Makukh has nothing to disclose. K. Malakauskas has nothing to disclose. E.F. McKone reports grants or contracts from vertex, outside the submitted work; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Vertex Pharmaceuticals and Roche Pharmaceuticals, outside the submitted work; support for attending meetings and/or travel from A Menarini, outside the submitted work; participation on a Data Safety Monitoring Board or Advisory Board for Insmed and Janssen Pharmaceuticals, outside the submitted work. M. Mei-Zahav has nothing to disclose. I. de Monestrol reports grant from Vertex for an academic research study regarding gastrointestinal outcome in CF patients taking Orkambi medication, outside the submitted work; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid from Swedish CF Registry and the Swedish Society of Medicine’s CF working group. H.V. Olesen has nothing to disclose. R. Padoan has nothing to disclose. T. Parulava has nothing to disclose. M.D. Pastor-Vivero has nothing to disclose. L. Pereira has nothing to disclose. G. Petrova reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from TEVA Pharmaceuticals, Mylan and Alvogen, outside the submitted work. A. Pfleger has nothing to disclose. L. Pop has nothing to disclose. J.G. van Rens has nothing to disclose. M. Rodić has nothing to disclose. M. Schlesser has nothing to disclose. V. Storms has nothing to disclose. O. Turcu has nothing to disclose. L. Woźniacki has nothing to disclose. P. Yiallouros has nothing to disclose. A. Zolin has nothing to disclose. D.G. Downey has nothing to disclose. L. Naehrlich reports support for the present manuscript from Chiesi Farmaceutici SpA; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from ArticulateScience LLC, outside the submitted work; participation on a Data Safety Monitoring Board or Advisory Board for Trial Steering committee of CF Storm, outside the submitted work; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid from Society for German CF Registry European CF Patient Registry, outside the submitted work; other financial or nonfinancial interests from Vertex Pharmaceuticals and Boehringer Ingelheim; Institutional fees for site participation (PI) in clinical trials from Vertex Pharmaceuticals and Boehringer Ingelheim.

Support statement: This paper was supported by an unrestricted grant from Chiesi Pharmaceuticals, Italy. The funder had no role in the planning, conduct, analysis or reporting of the study, nor did they review the draft paper before submission. Funding information for this article has been deposited with the Crossref Funder Registry.

References

1 World Health Organisation. Weekly epidemiological update – 29 December 2020. www.who.int/publications/m/item/weekly-epidemiological-update—29-december-2020 Date last updated: 29 December 2020. Date last accessed: 23 March 2021.

2 Viviani L, Assael BM, Kerem E, et al. Impact of the A (H1N1) pandemic influenza (season 2009–2010) on patients with cystic fibrosis. J Cyst Fibros 2011; 10: 370–376.

3 Kiedrowski MR, Bomberger JM. Viral-bacterial co-infections in the cystic fibrosis respiratory tract. Front Immunol 2018; 9: 3067.

4 Dennis JB, Jones AM, Davies EA, et al. Influenza B outbreak at an adult cystic fibrosis centre: clinical impact and factors influencing spread. J Cyst Fibros 2020; 19: 808–814.
Corvol H, de Miranda S, Lemonnier L, Mondejar-Lopez P, Quintana-Gallego E, Giron-Moreno RM, Pellegrino R, Viegi G, Brusasco V, Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression.

Zolin A, Orenti A, Naehrlich L, Buitrago-Garcia D, Egli-Gany D, Counotte MJ, European Centre for Disease Control. Data on testing for COVID-19 by week and country. https://www.ecdc.europa.eu/en/publications-data/covid-19-testing-data last updated: 25 November 2021. Date last accessed: 26 November 2021.

International Society of Heart and Lung Transplantation (ISHLT). Guidance from the International Society of Heart and Lung Transplantation regarding the SARS CoV-2 pandemic. https://ishlt.org/ishlt/media/documents/SARS-CoV-2_Guidance-for-Cardiothoracic-Transplant-and-VAD-center.pdf Date last updated: 1 February 2021. Date last accessed: 31 March 2021.

European Centre for Disease Control. Data on testing for COVID-19 by week and country. https://www.ecdc.europa.eu/en/publications-data/covid-19-testing-data last updated: 25 November 2021. Date last accessed: 26 November 2021.

International Society of Heart and Lung Transplantation (ISHLT). Guidance from the International Society of Heart and Lung Transplantation regarding the SARS CoV-2 pandemic. https://ishlt.org/ishlt/media/documents/SARS-CoV-2_Guidance-for-Cardiothoracic-Transplant-and-VAD-center.pdf Date last updated: 1 February 2021. Date last accessed: 31 March 2021.

Brugnano A, Ceresa M, Del Buffo M, et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: a living systematic review and meta-analysis. PLoS Med 2020; 17: e1003346.

Agyeman AA, Chin KL, Landersdorfer CB, et al. Smell and taste dysfunction in patients with COVID-19: a systematic review and meta-analysis. Mayo Clin Proc 2020; 95: 1621–1631.

Lindig J, Steger C, Beiersdorf N, et al. Smell in cystic fibrosis. Eur Arch Otorhinolaryngol 2013; 270: 915–921.

Karagiannidis C, Windisch W, McAuley DF, et al. Major differences in ICU admissions during the first and second COVID-19 wave in Germany. Lancet Respir Med 2021; 9: e47–e48.

Chalmers JD, Crichton ML, Goeminne PC, et al. Management of hospitalised adults with coronavirus disease-19 (COVID-19): A European Respiratory Society living guideline. Eur Respir J 2021; 57: 2100048.

Peckham D, McDermott MF, Savic S, et al. COVID-19 meets Cystic Fibrosis: for better or worse? Genes Immun 2020; 21: 260–262.

Centers for Disease Control and Prevention (CDC). Evidence used to update the list of underlying medical conditions that increase a person’s risk of severe illness from COVID-19. www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/evidence-table.html Date last updated: 29 March 2021. Date last accessed: 22 December 2020.

Raja MA, Mendoza MA, Villavicencio A, et al. COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis of current literature. Transplant Rev (Orlando) 2021; 35: 100588.

Saez-Gimenez B, Berastegui C, Barrecheguren M, et al. COVID-19 in lung transplant recipients: a multicenter study. Am J Transplant 2020; 21: 1816–1824.

Kapriniotis K, Giannis D, Geroupolos G, et al. Heart and lung transplantation in the Era of COVID-19: early recommendations and outcomes. Exp Clin Transplant 2021; in press [https://10.6002/ect.2020.0289].

International Society of Heart and Lung Transplantation (ISHLT). SARS-CoV-2 Vaccination in Heart and Lung Transplantation: Recommendations from the ISHLT COVID-19 Task Force. https://islt.org/islt/media/Documents/COVID19_Vaccine-Recommendations_3-15-2021.pdf Date last updated: 15 March 2021. Date last accessed: 31 March 2021.

Recovery Collaborative Group. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2021; 397: 605–612.

Saiman L, Siegel J. Infection control in cystic fibrosis. Clin Microbiol Rev 2004; 17: 57–71.
32 Castellani C, Duff AJA, Bell SC, et al. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros 2018; 17: 153–178.

33 Nichols DP, Odem-Davis K, Cogen JD, et al. Pulmonary outcomes associated with long-term azithromycin therapy in cystic fibrosis. Am J Respir Crit Care Med 2020; 201: 430–437.

34 McGurnaghan SJ, Weir A, Bishop J, et al. Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. Lancet Diabetes Endocrinol 2021; 9: 82–93.

35 Bridges N, Rowe R, Holt RIG. Unique challenges of cystic fibrosis-related diabetes. Diabet Med 2018; 35: 1181–1188.

36 Hasan S, Cecilia Lansang M, Salman Khan M, et al. Managing Cystic Fibrosis related diabetes via telehealth during COVID-19 pandemic. J Clin Transl Endocrinol 2021; 23: 100253.

37 Booth A, Reed AB, Ponzo S, et al. Population risk factors for severe disease and mortality in COVID-19: a global systematic review and meta-analysis. PLoS ONE 2021; 16: e0247461.

38 Peckham H, de Gruijter NM, Raine C, et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun 2020; 11: 6317.

39 Lam GY, Goodwin J, Wilcox PG, et al. Sex disparities in cystic fibrosis: review on the effect of female sex hormones on lung pathophysiology and outcomes. ERJ Open Res 2021; 7: 00475-2020.

40 Kuczynski RJ, Ogden CL, Guo SS, et al. 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 11 2002; 246: 1–190.